610 results
Page 15 of 31
8-K
EX-99.1
qc4em9 ay0a1
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.2
votc jd5i6l
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.2
y4lhcx2 znhva4
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
8uczdxl9
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
SC TO-T/A
EX-99
egd2j8kbhr8 4rd6l2
29 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
f252s759reb6h6uceq7
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
8-K
EX-99.2
t0dxuoeosp94x3
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am